Accumulating evidence shows a key function for astrocytic connexin43 (Cx43) signaling in epilepsy. However, the lack of experimental distinction between Cx43 gap junction channels (GJCs) and hemichannels (HCs) has impeded the identification of the exact contribution of either channel configurations to epilepsy. We therefore investigated whether TAT-Gap19, a Cx mimetic peptide 
| I N TR ODU C TI ON
Despite the large number of marketed anti-seizure drugs (ASDs), one third of patients with epilepsy suffer from intolerable side effects and/ or drug resistance (Kwan, Schachter, & Brodie, 2011) . Pharmacoresistance to several ASDs can be explained by the similar mechanisms of action, which are mainly targeting neuronal mechanisms (Janigro & Walker, 2014) . The discovery of ASDs with distinct activity profiles (e.g., targeting non-neuronal elements) has therefore become an important new avenue for the development of epilepsy treatments (Baulac & Pitkänen, 2008) . In line with this notion, the present study evaluates the potential of astroglial connexin (Cx) hemichannels (HCs) as novel druggable targets for epilepsy. Astrocytes express Cx43 and Cx30;
here we focus on Cx43 as the major astrocytic Cx (Orellana, Retamal, Moraga-Amaro, & Stehberg, 2016) .
Cx43 proteins are building blocks of two different channel types in astrocytes (Nagy & Rash, 2000; Naus, Bechberger, Caveney, & Wilson, 1991; Orellana et al., 2016) . While Cx43 gap junction channels (GJCs) connect two adjacent astrocytes, Cx43 HCs are located between the cytosol of a single astrocyte and the extracellular environment (Abudara et al., 2014) . When open, Cx43 HCs form a high conductance pathway (single channel conductance of 220 pS) allowing the passage of molecules and ions below 1.5 kDa (Wang et al., 2012) . Some controversies regarding the functional characteristics of Cx43 HCs are described (reviewed in Nielsen, Hansen, Ransom, Nielsen, & MacAulay, 2017) , however, several research papers demonstrate that, if opening is limited in nature, glial Cx43 HCs may provide a pathway for controlled release of various neuroactive substances, called gliotransmitters (e.g., glutamate and adenosine triphosphate (ATP) release ; Orellana et al., 2011; Ye, Wyeth, Baltan-Tekkok, & Ransom, 2003) or the entry of major signaling ions like Ca
21
. The latter will transiently increase the intracellular Ca 21 concentration ([Ca 21 ] i ), which can affect a variety of physiological cell functions (e.g., regulation of cell volume and synaptic activity; Chever, Lee, & Rouach, 2014; Chever, Pannasch, Ezan, & Rouach, 2014; Lohman & Isakson, 2014; Meunier et al., 2017; Giaume, Leybaert, Naus, & S aez, 2013; Orellana et al., 2016; Pannasch & Rouach, 2013; Torres et al., 2012; Walrave et al., 2016) .
Sustained Cx43 HC opening on the other hand could release excessive amounts of chemically active molecules (e.g., damageassociated ATP release), lead to disturbed transmembrane ion fluxes and loss of essential metabolites. Cx43 HC opening might therefore promote deleterious results, which has been demonstrated in several pathological conditions, such as ischemia, Alzheimer's disease and inflammation (Abudara et al., 2015; De Bock et al., 2014; Giaume et al., 2013; Montero & Orellana, 2015; Vinken, 2015; Wei et al., 2014) .
While in vivo glutamate release linked to Cx43 HC opening has already been demonstrated in a hypoxia/ischemia rat model (Li et al., 2015; use of Gap26 mimetic peptide), up to now no in vivo reports are available pinpointing the contribution of Cx43 HCs to D-serine release. Their potential function as pathological pores as well as their predominant and high expression by astrocytes in the hippocampus (Chever, Lee, et al., 2014; Giaume & Theis, 2010; Kang et al., 2008; Mylvaganam et al., 2010; Ye et al., 2003) , a brain region crucially involved in epilepsy, led us to hypothesize that in vivo Cx43 HC inhibition may be a novel treatment strategy for epilepsy.
An increasing number of studies point to a role for Cx43 signaling in epilepsy (for reviews see Carlen, 2012; Jin & Chen, 2011; Mylvaganam, Ramani, Krawczyk, & Carlen, 2014) . Nevertheless, due to a lack of experimental tools, the exact contribution of either Cx43 HC or Cx43
GJC inhibition in epilepsy remains to be elucidated. Indeed, the use of Cx knock-out animals or non-selective inhibitors have led to contradictory results, resulting in either proconvulsant or anticonvulsant effects (Carlen, 2012) . In knock-out mice, both HCs and GJCs are deleted, as these channels are built up by the same proteins, and compensatory mechanisms are possible (Nielsen et al., 2017; Suadicani, De PinaBenabou, Urban-Maldonado, Spray, & Scemes, 2003; Theis et al., 2003) . Previously used inhibitors have poor selectivity for different Cx species, affect both HCs and GJCs, and have significant effects on other targets (e.g., pannexin HCs and voltage-gated Ca 21 channels; Carlen, 2012; Herv e & Sarrouilhe, 2005; Jin & Chen, 2011; Nielsen et al., 2017; Willebrords, Maes, Crespo Yanguas, & Vinken, 2017) .
To explore the role of Cx43 HCs in seizures, we used TAT-Gap19 to block HC function without reducing GJCC via Cx43-based channels (Abudara et al., 2014) . Gap19 is a synthetic nonapeptide derived from the intracellular L2 domain of Cx43 and specifically disturbs intramolecular interactions between the cytoplasmic loop (CL) and the carboxyterminal tail (CT) (Wang et al., 2013a; Figure1) . These loop-tail interactions distinctly affect Cx43 HCs and GJCs, with GJCs being closed by these interactions, while HCs need these interactions to become available to open with electrical or chemical triggers (Wang et al., 2013b , Iyyathurai et al., 2013 reviewed in Leybaert et al., 2017) . Gap19 has been demonstrated to inhibit Cx43 HCs while having no effect on Cx40 HCs, pannexin1 channels (Wang et al., 2013a) and Cx43 GJs (Abudara et al., 2014) . The peptide targets and interacts with a sequence on the intracellular C-terminal domain, which is indeed very different between distinct Cxs, while the extracellular regions (e.g., targeted by Gap26, Gap27) are very well conserved (Wang et al., 2013a) .
As a result, Gap19 has intrinsically less chance of interacting with Cxs other than Cx43.
In the present study, we first performed in vitro mechanistic experiments in hippocampal slices demonstrating that the chemoconvulsant pilocarpine induces astroglial Cx43 HC opening which was blocked by the Cx43 HC inhibitor TAT-Gap19. Next, we carried out in vivo experiments to assess the effect of TAT-Gap19 on pilocarpineinduced limbic seizures and gliotransmitter release. Finally, we further explored the therapeutic potential of Cx43 HC inhibition in an acute and chronic electrical seizure mouse model of refractory seizures.
| M A TER I A LS A N D M ETH OD S

| Animals
Animals were housed at constant temperature (218C 6 38C)/relative humidity (55% 6 10%) in a 12/12 hr light/dark cycle with free access to food and water. All efforts were made to minimize the number of animals used, their suffering and results are reported in accordance
with the ARRIVE guidelines (Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010) . Acute brain slices were obtained from 2-month-old GFAP-eGFP transgenic mice of either sex, generated in the SPF animal facility of Collège de France. In these mice, astrocytes are labeled by the enhanced green fluorescent protein (eGFP) under the control of the human glial fibrillary acidic protein (GFAP) promotor, to be able to visualize astrocytes by direct fluorescence microscopy (Nolte et al., 2001 ).
Experiments were performed according to the European Community
Council Directives (2010/63/EU).
In vivo experiments were performed on male NMRI mice weighing 20-30 g and male Wistar rats weighing 250-300 g at time of surgery (Charles River Laboratories, Châtillon-sur-Chalaronne, France). Animals acclimatized at least 1 week to the animal facility and 1 day to the experimental room before being used in experiments. All procedures were carried out in accordance with the National Rules on Animal Experiments and were approved by the Ethical Committee for Animal
Experiments of the Vrije Universiteit Brussel, Belgium.
| Experimental design
Slices or animals were randomly assigned to an experimental group and results were obtained as follows: automated software was used for dye uptake experiments and liquid chromatography analyses. For the focal pilocarpine mouse model, total seizure duration (depicted on electroencephalographic (ECoG) recordings) was counted blinded to treatment.
For the focal pilocarpine rat model and acute 6 Hz mouse model, syringes were coded by another experimenter. As experiments cannot be performed blinded in the 6 Hz corneal kindling model, behavior was scored by two independent experimenters. Sample size was determined a priori based on previous experience with the models.
| Connexin inhibitors and control peptides
Carbenoxolone (CBX; MW 614.72 g/mol, Sigma-Aldrich, Steinheim, Germany), a glycyrrhetinic acid derivate, was used as a non-selective Cx channel inhibitor (positive control). TAT-Gap19 (MW 2703 Da),
TAT-Gap19I130A, scrambled TAT-Gap19 and TAT (MW 1560 Da) were synthesized by Pepnome Inc. (Hong Kong, China, >95% purity)
or Genosphere Biotechnologies (Paris, France, >95% purity; Table 1 ).
TAT-Gap19 was used as a Cx43 HC inhibitor. Gap19 was coupled to the transactivator of transcription (TAT)-sequence of the HIV-1 virus to increase its cell membrane permeability, as the CT target is intracellularly located (Wang et al., 2013a Acute brain slices were incubated with oxygenated aCSF with or without inhibitor (CBX, TAT-Gap19) or negative control peptide (here TAT and scrambled TAT-Gap19). Since the lack of effect with 100 mM TAT-Gap19 (Wang et al., 2013a) in our first slice experiments (n 5 3), we opted to use 200 mM inhibitor for the remainder of the experiments.
Pilocarpine (15 mM, Sigma-Aldrich, Steinheim, Germany) was added to the incubation chambers (except for control condition) and slices were treated for 40 min to trigger HC activity in astrocytes. The test conditions included: (a) control where slices were only exposed to aCSF 15 min before and during pilocarpine treatment (i.e., CBX 1 P40, TG19 1 P40, TAT 1 P40, scrTG19 1 P40, respectively). Next, the HC permeable fluorescent tracer ethidium bromide (EtBr; 4 mM, SigmaAldrich, Steinheim, Germany) was incubated for 10 min at RT as previously described (Giaume, Orellana, Abudara, & S aez, 2012 other's cannulas and were allowed to recover for 7 days. A stylus (Bilaney Consultants, Düsseldorf, Germany) was placed inside the guide cannula to preclude clogging.
Wistar rats were anesthetized with a mixture of ketamine:diazepam (start dose 90.5:4.5 mg/kg i.p.; ketamine 1000 Ceva, Ceva Sante Animale; Valium, Roche, both Brussels, Belgium). A microdialysis guide (MAB6.14.IC, Microbiotech/se AB, Stockholm, Sweden) was implanted stereotactically above the left hippocampus (from bregma, mm: AP -5.6, ML 1 4.6; and 24.6 below dura mater). Two anchor screws were placed in the skull and dental cement was applied to fixate the guide cannula to the skull.
After surgery, mice and rats received 1 or 5 ml saline i.p. respectively to prevent dehydration and were placed in front of an infrared lamp or on a heating mat for 15 min to safely raise core body tempera- 
| Focal pilocarpine model in mice
After removing the inner guide cannula, an MAB6.10.2 probe (2 mm membrane, 15 kDa cut-off, Microbiotech/se AB, Stockholm, Sweden) was inserted and probes were continuously perfused with modified
Ringer's solution containing (in mM) NaCl (147), KCl (4) 
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Tilburg, The Netherlands) coupled to the Notocord-hem Evolution acquisition software (Notocord, Croissy-sur-Seine, France). During the microdialysis experiment, the ECoG was sampled with a frequency of 100 Hz and total seizure duration was calculated as the sum of the duration of all individual seizures by a scientist blinded to treatment.
Calculation of one seizure started from the time of identifiable change of ECoG activity to the end of ictal ECoG activity and these changes had to last for minimum 5 s. Two consecutive seizures were counted as one seizure when they were separated with less than 30 s.
| Focal pilocarpine model in rats
The in vivo microdialysis pretreatment protocol in freely-moving rats was similar to the one described above in mice. We however used an MAB6.14.3 probe (3 mm membrane length, 15 kDa cut-off, Microbiotech/se AB, Stockholm, Sweden). The detailed protocol is given in Fig- ure 5, upper panel.
Since rats show typical seizure-related behavioral changes in this model, a modified Racine's scale was used to score seizure severity with stages (0) normal, non-epileptic behavior, (1) mouth and facial movements, hyperactivity, excessive grooming, sniffing, scratching, wet dog shakes, (2) head-nodding, staring, tremor, (3) forelimb clonus/ extension, (4) rearing, salivating, tonic-clonic activity and (5) falling (Racine, 1972) . This scale was previously validated by our research group by ECoG monitoring (Meurs, Clinckers, Ebinger, Michotte, & Smolders, 2008) . For every 20 min, the highest seizure severity score (SSS) was assigned, starting from pilocarpine perfusion until the end of the experiment (in total 140 min or seven collection periods). The total seizure severity score (TSSS) for each animal is calculated as the sum of these seven SSSs and was used as a measure of seizure severity.
| Acute 6 Hz mouse model of refractory seizures
Limbic psychomotor seizures were evoked via corneal stimulation (6 Hz, 0.2 ms rectangular pulse width, 3 s duration) using an ECT Unit 57800 stimulator (Ugo Basile, Varese, Italy). All experiments were performed at a current intensity of 49 mA, found to be optimal in a current-response study (Walrave et al., 2015) . A drop of 0.5% xylocaine (AstraZeneca, Brussels, Belgium) in saline was applied to the eyes to induce local anesthesia and ensure good conductivity. After stimulation, the animals were gently placed in an open plastic cage (35 3 55 cm) to observe the presence or absence of seizure activity, which is characterized by stun, forelimb clonus and/or elevated Straub-tail. For each animal, the total seizure duration was manually recorded by a scientist blinded for treatment.
For the i.c.v. experiments, in which compounds are directly delivered into the ventricle, the stylus was removed from the guide cannula on the day of the experiment and a 33 GA injection cannula (Bilaney Consultants, D€ usseldorf, Germany) was inserted through the guide cannula, extending 1 mm beyond its tip in the ventricle. TAT-Gap19, its inactive mutant peptide (TAT-Gap19I130A), TAT (all 1 mM solutions) or vehicle (PBS) was infused in the ventricle via the injection cannula for 2 min at a flow rate of 0.5 ml/min (total 1 ml; CMA 400 Syringe Pump, CMA Microdialysis, Kista, Sweden), 60 min prior to the corneal stimulation. Following drug infusion, injection cannulas were left in place for 1 min to allow drug diffusion away from the cannula tip. Thus, mice received either 2.7 mg/ml (1 nmol/ml) TAT-Gap19, 2.7 mg/ml
(1 nmol/ml) TAT-Gap19I130A, 1.56 mg/ml (1 nmol/ml) TAT or 1 ml PBS i.
c.v. We previously demonstrated TAT-Gap19 diffusion from ventricle to hippocampus .
For the i.p. experiments, 25 mg/kg TAT-Gap19, its inactive scrambled version (25 mg/kg scrambled TAT-Gap19) or vehicle (0.9% NaCl) was administered 60 min prior to the corneal stimulation.
| Chronic 6 Hz corneal kindling mouse model
Initially, we explored different current intensities, applied once, to find a subconvulsive current intensity in male NMRI mice (i.e., 19 mA, data not shown). These animals were not included in the actual kindling experiment.
Mice were stimulated twice daily (between 8-10 hr and 14-16 hr, Monday to Friday) at a fixed, initially subconvulsive threshold current were included in the experiments. All fully-kindled animals used in the experiments met these criteria (100% inclusion rate). Seizure severity was assessed by two independent experimenters and scores following vehicle and TAT-Gap19 administration were compared. 
| Data analyses and statistics
Statistical analyses were performed using GraphPad Prism 6.01 (Graph- This effect was suppressed by CBX (200 mM), a non-selective blocker that inhibits both Cx and pannexin channels at the concentration applied, suggesting that EtBr uptake occurred through Cx HCs or pannexin channels (CBX 1 P40: 77.13% 6 22.65% of control, n 5 7, two-sided WMS, p 5 .0156 compared with P40).
The pilocarpine-induced EtBr uptake in astrocytes was also significantly decreased by 200 mM TAT-Gap19 (TG19 1 P40:
140.20% 6 12.06% of control, n 5 8, two-sided WMS, p 5 .0078 compared with P40). As TAT-Gap19 is a more specific Cx43 HC blocker, this suggests that substantial astrocytic dye uptake occurred through HCs composed of Cx43.
There were no significant differences between pilocarpine treated slices and slices that were pre-treated with each of the TAT-Gap19 control peptides, namely the TAT sequence alone (TAT 1 P40:
200.08% 6 18.96% of control, n 5 7, p 5 .4375 compared with P40) and the scrambled version of TAT-Gap19 (scrTG19 1 P40:
207.10% 6 44.84% of control, n 5 7, p 5 .5781 compared with P40, both two-sided WMS). Importantly, TAT-Gap19 significantly decreased
EtBr uptake compared with the control peptides (TAT 1 P40 and scrTG19 1 P40 both p 5 .0313 compared with TG19 1 P40, both twosided WMS). By contrast, the CBX and TAT-Gap19 condition did not significantly differ from the concurrent control condition (CBX 1 P40 On the contrary, when TAT-Gap19 was administered 20 min after seizure onset, the total seizure duration from mice receiving 50 mM TAT-Gap19 (3,423 6 934 s, n 5 6) did not significantly differ from the control mice receiving vehicle (3,743 6 813 s, n 5 6, two-sided MannWhitney test, U 5 14.00, p 5 .5714), implicating that Cx43 HC FIG URE 2 Pilocarpine treatment increases ethidium bromide (EtBr) uptake through astrocytic hemichannels (HCs) in acute hippocampal slices. (a) Averaged data normalized to control (Ctr) (dashed line) of EtBr uptake in GFAP-eGFP positive hippocampal astrocytes treated for 40 min with pilocarpine (15 mM) alone (P40) and in presence of the non-selective Cx/pannexin channel inhibitor carbenoxolone (CBX 1 P40), the Cx43 HC inhibitor TAT-Gap19 (TG19 1 P40) and its two negative control peptides TAT (TAT 1 P40) and scrambled TATGap19 (scrTG19 1 P40), all applied at 200 mM, 15 min before pilocarpine treatment and during dye uptake measurement. (b) Fluorescence representative images of acute hippocampal slices derived from GFAP-eGFP transgenic mice show GFAP-eGFP astrocytes (green) and EtBr uptake (red). Images of hippocampal astrocytes were taken from the CA1-CA3 interpyramidal zone. Statistics: (a) Two-sided Wilcoxon matched-pairs signed-rank test with ***p < .001, *p < .05: significant increase compared with Ctr; $$p < .01, $p < .05: significant decrease compared with P40, #p < .05 significant difference between TAT-Gap19 and control peptides inhibition was unable to interrupt full-blown seizure activity (Supporting Information Figure S2 ).
To evaluate whether Cx43 HCs contribute to gliotransmitter release in vivo during seizures, D-serine was analyzed in the microdialysis samples of a subset of mice receiving 25 mM TAT-Gap19 and 25 mM scrambled TAT-Gap19 (pretreatment protocol).
Since baseline D-serine dialysate levels were not different between scrambled TAT-Gap19 (0.32 6 0.06 mM, n 5 6) and TAT-Gap19 treated animals (0.34 6 0.04 mM, n 5 9; two-sided Mann-Whitney test, however failed to significantly decrease seizure duration compared with vehicle (0.9% NaCl i.p., 44 6 8 s, n 5 8, two-sided Mann-Whitney test, U 5 12.00, p 5 .0718, data not shown).
3.6 | TAT-Gap19 decreases seizure severity in the 6 Hz corneal kindling mouse model
Next, TAT-Gap19 was evaluated in the chronic 6 Hz corneal kindling model, which is considered as a model of treatment-resistant epilepsy since partial seizures persist despite treatment with high doses of ASDs (Leclercq, Matagne, & Kaminski, 2014) . Figure S3 ). 
| D ISC USSION
We here tested whether Cx43 HC inhibition with TAT-Gap19 could influence seizure activity in in vivo rodent models. Various models were applied to that purpose, including focal microdialysis-delivered pilocar- (Johnson et al., 2016) . We found that both CBX and TAT-Gap19 significantly decreased pilocarpine-induced EtBr uptake in GFAP-positive astrocytes. CBX has a larger spectrum of effects, which includes inhibition of Cx-based GJCs and HCs (e.g., astrocytic Cx30 (Hansen et al., 2014; Pannasch et al., 2014) and neuronal Cx36 (Allison et al., 2011) as well as pannexin-based channels (Bruzzone, Barbe, Jakob, & Monyer, 2005) . Moreover, CBX has several other well-known off-target effects, including the inhibition of voltage-gated Ca 21 currents and synaptic transmission, as well as effects on gammaaminobutyric acid (GABA) receptors that all largely affect electrical excitability (Connors 2012; Vessey et al., 2004) . None of the control peptides affected EtBr uptake in pilocarpine treated slices, so effects of TAT-Gap19 resulted from Cx43 HC inhibition as this peptide was demonstrated not to affect pannexin1 channels (Wang et al., 2013ba) . Of note, we used GFAP-eGFP expressing transgenic mice as a tool to visualize astrocytes. In these mice, not all astrocytes are GFAP-positive and we also observed EtBr uptake in GFAP-negative cells, which may represent neurons, GFAP-negative astrocytes (Houades et al., 2006) or microglial cells as reported by others (Abudara et al., 2014) . As pilocarpine acts on neurons, it is conceivable that most of these cells are neurons, especially since TAT-Gap19 did not diminish the EtBr uptake and adult neurons do not express Cx43 (Theis et al., 2003) . Here, we only effect on neuronal muscarinic M1 receptors and triggers epileptiform activity in hippocampal slices (Portelli et al., 2012 (Somjen, 2002 (Wang et al., 2012) , may also directly trigger HC opening in voltage clamped astrocytes at 270 mV (Meunier et al., 2017; reviewed in Leybaert et al., 2017) . Astrocytic [Ca 21 ] i elevation is a common theme in various epilepsy models (Carmignoto & Haydon, 2012) , making it a likely trigger for epileptic Cx43 HC opening.
Additionally, since pilocarpine was acutely added to the slices, we demonstrated the involvement of astrocytic Cx43 HCs in epileptiform activity. Opening of astrocytic Cx43 HCs may contribute to the seizurogenic effect of pilocarpine by loss of essential cellular metabolites, by disturbed transmembrane ion fluxes (De Bock et al., 2014; Giaume et al., 2013; Montero & Orellana, 2015; Wei et al., 2014) , by possibly leading to cell swelling, by provoking cell death and/or by releasing (excitatory) gliotransmitters (e.g., glutamate, D-serine; Orellana et al., 2011; Stehberg et al., 2012) . Glutamate is the major excitatory transmitter in the brain and elevated levels have been reported in human brain tissues of patients with epilepsy and animal models of epilepsy. Elevated extracellular glutamate concentrations can induce N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity, which causes neuronal death in epilepsy (Cho, 2013) . Besides glutamate, astrocyte-released D-serine acts as an important modulator of NMDA receptors, thereby promoting their opening, increasing excitability and seizure generation (Clasadonte & Haydon, 2012) .
The detailed mechanism underlying astrocytic D-serine release is still unknown but is in general assumed to be dependent on an increase in cytosolic Ca
21
. Astrocytic D-serine release has been reported to occur via large vesicles and Ca
-dependent exocytosis (Orellana & Stehberg, 2014) . Moreover, a recent study performed in prefrontal cortex slices has shown that in basal conditions, D-serine released by astrocytes is associated to Cx43 HC activity and is triggered by increases in [Ca 21 ] i in astrocytes voltage clamped at 270 mV (Meunier et al., 2017) . Up to now, only one in vivo study proposed that astrocytic Cx43 HCs might release D-serine (Stehberg et al., 2012) . In this paper, Stehberg and colleagues investigated the effect of Cx43 HC inhibition in a fear-based memory paradigm by using another Cx43 HC inhibitor called TAT-L2. Of note, the L2 peptide is composed of a sequence which comprises the Gap19 sequence used in the present study; in fact, the Gap19 sequence is the most active part within the L2 sequence (Wang et al., 2013a) . TAT-L2 impaired fear memory consolidation in the basolateral amygdala and the effect was reversed by administering a cocktail of gliotransmitters (glutamate, glutamine, lactate, D-serine, glycine, and ATP). The authors therefore postulated that gliotransmitter release from astrocytes occurred through Cx43 HCs.
Although this study nicely supports the hypothesis that Cx43 HCs contribute to gliotransmission, the exact gliotransmitters released were not identified nor measured.
We here show for the first time that seizure-enhanced D-serine dialysate levels can be diminished by TAT-Gap19, suggesting that properties. Regardless, TAT-Gap19 was also CNS-active after systemic administration, indicating favorable blood-brain permeability properties and the possible application as a drug. Different TAT-Gap19 doses were required depending on the used model (i.e., distinct seizure induction, administration routes, species and seizure severity assessments).
In conclusion, our study is the first to demonstrate that attenuation of D-serine dialysate levels is crucial for the anticonvulsant properties of TAT-Gap19. We propose Cx43 HCs as a novel and druggable target against seizures, encouraging the further assessment of Cx43 HC blockers in additional chronic models of epilepsy.
